Originally published in Law360 on April 12, 2021, 6:58 PM EDT.

Law360’s 2021 Life Sciences Editorial Board

Law360 (April 12, 2021, 6:58 PM EDT) — Law360 is pleased to announce the formation of its 2021 Life Sciences Editorial Advisory Board.

The editorial advisory board provides feedback on Law360’s coverage and expert insight on how best to shape future coverage.

The members of Law360’s 2021 Life Sciences Editorial Advisory Board are:

Michael J. Abernathy, Morgan Lewis & Bockius LLP
Michael Abernathy is the co-leader of Morgan Lewis’ IP disputes practice and life sciences industry initiative and concentrates on patent, trade secret and antitrust litigation. He has first chair trial experience in pharmaceutical and technology cases and is highly sought after by clients that face significant “bet-the-company” litigation.

Kellie Combs, Ropes & Gray LLP
Kellie Combs focuses her practice on the U.S. Food and Drug Administration’s regulation of pharmaceuticals, biotechnology and medical devices. She regularly represents clients before the agency at all phases of the product life cycle, assisting with regulatory due diligence in transactions involving FDA-regulated products, and advising on internal and government compliance investigations and enforcement actions.

Elizabeth Flanagan, Fish & Richardson PC
Betsy Flanagan is a principal in the Twin Cities office of Fish & Richardson. Her practice focuses on complex patent litigation, with an emphasis on life sciences, biotechnology and pharmaceutical litigation, including Hatch-Waxman Act litigation.

Sharonmoyee Goswami, Cravath Swaine & Moore LLP
Sharonmoyee Goswami is a partner in Cravath’s litigation department, focusing on intellectual property, antitrust and litigation. Her clients include biotechnology, pharmaceutical and medical device companies. Her extensive patent litigation experience draws upon her chemical engineering background and her time clerking at the Federal Circuit for U.S. Circuit Judge Timothy B. Dyk.

Dr. Katherine A. Helm, Dechert LLP
Katherine A. Helm, Ph.D. represents innovative companies in intellectual property matters, with a focus on biopharmaceutical patent litigation. Her neuroscience doctorate allows her to offer a unique perspective to life sciences companies in all phases of litigation. She is fluent in French and often involved in disputes with multijurisdictional aspects.

Laurie Hill, Genentech
As the vice president of intellectual property at Genentech, Dr. Laurie Hill leads an energetic team in creating high-value, global portfolios that enable delivery of innovative medicines to patients. She holds a J.D. from the University of Texas School of Law and a Ph.D. in microbiology and immunology from Thomas Jefferson University.

Matt Holian, DLA Piper
COVID-19 focused the world’s attention on the contributions of life science innovators. As global co-chair of DLA Piper’s life sciences sector, Matt Holian represents some of the most significant life science companies racing to thwart the pandemic while also working to take promising therapies from the laboratory to the market.

Winston S. Kirton, Winston & Strawn LLP
Winston Kirton has significant international legal and business life sciences experience developed over many years working in-house for several large multinational biopharmaceutical companies. He leverages his international in-house experience in quality and compliance, regulatory affairs, compliance and ethics, and legal affairs to provide end-to-end advice and counsel to his clients.

Steve Lendaris, Baker Botts LLP
As chair of Baker Botts’ life sciences IP practice group, partner Steve Lendaris advises clients on a wide range of biotechnology-related intellectual property issues. Lendaris’ value-add is providing technically informed and commercially relevant legal advice that the scientists, the in-house legal team and the C-suite can all understand.

Y. John Lu, Milbank LLP
Dr. Y. John Lu is a partner at Milbank LLP and a patent litigator representing clients in patent infringement, U.S.-China trade secret misappropriation, biosimilars, ANDA litigation, life sciences litigation and licensing disputes. He also represents clients in proceedings before the Patent Trial and Appeal Board.

Yvonne Puig, Norton Rose Fulbright
Yvonne Puig, Norton Rose Fulbright’s U.S. chief integration partner for life sciences and health care, has a substantial commercial litigation practice in both state and federal courts. She represents large health systems, medical schools, institutional health care providers, for-profit educational companies, and managed-care organizations across the U.S.

Lisa L. Smith, Phillips Lytle LLP
Partner Lisa L. Smith co-chairs Phillips Lytle’s life sciences and health effects practice team. She has over 30 years of litigation experience focusing on high-stakes life sciences product liability litigation in class action and MDL settings, and often coordinates the scientific defenses to claims regarding drugs, devices and consumer products.

William T. Whelan, Mintz Levin Cohn Ferris Glovsky and Popeo PC
Mintz member and co-chair of the firm’s life sciences practice William T. Whelan counsels life science companies on public and private financings and mergers and acquisitions. He guides clients including biotechnology, medical technology and diagnostics companies through every stage of the corporate life cycle.